Global phase iii trial of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures

Authors
Category Primary study
ConferenceNeurology
Year 2011
This article has no abstract
Epistemonikos ID: 0f99ebe9b7d2db8695721f2b1964a2b26bf30e37
First added on: Apr 30, 2026